Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
复制标题
COVID-19的防治：重点关注干扰素、氯喹/羟氯喹、阿奇霉素和疫苗
DOI：
10.1016/j.biopha.2020.111008
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Yang G
中科院分区：
文献类型：
--
作者：
Bakadia BM;He F;Souho T;Lamboni L;Ullah MW;Boni BO;Ahmed AAQ;Mukole BM;Yang G
SARS-CoV-2感染诱导I型和III型IFN的低水平产生。抗病毒免疫力下降和细胞因子风暴导致严重的COVID-19。用I型IFN治疗显示出令人鼓舞的结果。CQ/HCQ和基于AZM的治疗由于不良反应而存在争议。COVID-19候选疫苗展示了有希望的结果。由严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）引起的持续大流行引起了来自多个学科和部门的研究人员和临床医生的注意，他们正在努力寻找预防和治疗层面的持久解决方案。到目前为止，没有批准的有效治疗方法或疫苗可用于控制2019冠状病毒病（COVID-19）。病毒感染模型的初步体外研究显示，I型和III型干扰素（IFN）、氯喹（CQ）/羟氯喹（HCQ）和阿奇霉素（AZM）具有潜在的抗病毒活性;然而，CQ/HCQ和AZM治疗COVID-19患者的临床研究因其不良副作用而在不同地区引起争议，并且其联合治疗可延长QT间期。有趣的是，用I型IFN治疗显示出令人鼓舞的结果。此外，COVID-19候选疫苗的不同初步报告通过在几乎所有参与者中诱导产生高水平的中和抗体（NAb）和特异性T细胞介导的免疫应答，展示了有希望的结果。本综述旨在总结和分析关于使用IFN、CQ/HCQ和AZM治疗COVID-19的最新进展证据。本集团亦分析了预防COVID-19的免疫方案的可用数据，旨在提出未来可供研究的有前景方案，以持续控制疫情。
SARS-CoV-2 infections induce low level production of type I and III IFNs. Reduced antiviral immunity and cytokine storm contribute to severe COVID-19. Treatment with type I IFN demonstrates encouraging results. CQ/HCQ and AZM-based treatments are controversial due to adverse effects. COVID-19 candidate vaccines showcase promising results. The ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has drawn the attention of researchers and clinicians from several disciplines and sectors who are trying to find durable solutions both at preventive and treatment levels. To date, there is no approved effective treatment or vaccine available to control the coronavirus disease-2019 (COVID-19). The preliminary in vitro studies on viral infection models showed potential antiviral activities of type I and III interferons (IFNs), chloroquine (CQ)/hydroxychloroquine (HCQ), and azithromycin (AZM); however, the clinical studies on COVID-19 patients treated with CQ/HCQ and AZM led to controversies in different regions due to their adverse side effects, as well as their combined treatment could prolong the QT interval. Interestingly, the treatment with type I IFNs showed encouraging results. Moreover, the different preliminary reports of COVID-19 candidate vaccines showcase promising results by inducing the production of a high level of neutralizing antibodies (NAbs) and specific T cell-mediated immune response in almost all participants. The present review aims to summarize and analyze the recent progress evidence concerning the use of IFNs, CQ/HCQ, and AZM for the treatment of COVID-19. The available data on immunization options to prevent the COVID-19 are also analyzed with the aim to present the promising options which could be investigated in future for sustainable control of the pandemic.
登录
查看更多内容
DOI：
10.1084/jem.20151267
发表时间：
2015-08-24
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Bournazos S;DiLillo DJ;Ravetch JV
通讯作者：
Ravetch JV
随机试验评估阿奇霉素对血清和上呼吸道IL-8水平的影响，并在患有呼吸道合胞病毒细支气管炎的婴儿中复发。
DOI：
10.1016/j.jaci.2014.10.001
发表时间：
2015-05
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Beigelman A;Isaacson-Schmid M;Sajol G;Baty J;Rodriguez OM;Leege E;Lyons K;Schweiger TL;Zheng J;Schechtman KB;Castro M;Bacharier LB
通讯作者：
Bacharier LB
影响因子：
158.5
作者：
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者：
Hullsiek, Kathy H.
DOI：
10.1016/j.ijpddr.2018.10.002
发表时间：
2018-12
期刊：
International journal for parasitology. Drugs and drug resistance
影响因子：
--
作者：
Aguiar ACC;Murce E;Cortopassi WA;Pimentel AS;Almeida MMFS;Barros DCS;Guedes JS;Meneghetti MR;Krettli AU
通讯作者：
Krettli AU
影响因子：
3.8
作者：
Andreani, Julien;Le Bideau, Marion;Raoult, Didier
通讯作者：
Raoult, Didier